IRVINE, Calif.--(BUSINESS WIRE)--Sep. 9, 2016--
Masimo (NASDAQ:
MASI) announced today that in a new study recently presented at the
World Congress of Anesthesiologists (WCA) in Hong Kong, researchers
concluded that continuous and noninvasive hemoglobin monitoring using
Masimo SpHb® may reduce excessive intraoperative red blood
cell (RBC) transfusion.1
In a retrospective review of 371 patients who underwent intraoperative
RBC transfusions between 2012 and 2014 at Fukushima Medical University
in Japan, Dr. Imaizumi and colleagues compared 94 patients who had
noninvasive hemoglobin measurements to 277 patients who did not (the
control group). The total transfusion volumes and transfusion volume per
1 g of blood loss were determined for each group.
Comparing the groups, researchers noted that “a significantly lower mean
RBC transfusion volume per 1 g of blood loss was observed in the SpHb
group compared with the [control] group (SpHb group, 0.9 ± 1.0 ml/g
blood loss vs [control] group, 2.4 ± 5.9 ml/g blood loss, p < 0.01).”
They also observed that there was “no significant difference…in the
average RBC transfusion volume (SpHb group, 815 ± 819 ml vs. [control]
group, 785 ± 773 ml, p=0.75), or the preoperative hemoglobin
concentration (SpHb group, 10.4 ± 1.9 g/dL vs. [control] group, 10.2 ±
2.4 g/dL, p=0.27) between the groups.” According to results from this
abstract, the authors concluded that “SpHb measurements are associated
with reducing excessive intraoperative RBC transfusion.”
“This is the third study, published by different researchers on three
continents (US2, Egypt3, and now Japan1),
that has shown that in addition to other clinical tools, SpHb may be
used to help clinicians make informed transfusion decisions during
different types of surgery*,” stated Dr. Steven Barker, Ph.D., M.D.,
Chief Science Officer, Masimo.
SpHb monitoring may provide additional insight to the directional trend
of hemoglobin between invasive blood samplings – when the SpHb trend is
stable and the clinician may otherwise think hemoglobin is decreasing;
when the SpHb trend is rising and the clinician may otherwise think
hemoglobin is not rising fast enough; or when the SpHb trend is
decreasing and the clinician may otherwise think hemoglobin is stable.
SpHb with laboratory diagnostic test may thus help clinicians make more
timely and informed decisions, and has been shown to help clinicians
provide more timely blood transfusions* and reduce blood transfusions in
cases such as neurosurgery and orthopedic surgery.2,3
Last week Masimo announced that in response to the Zika virus and its
potential impact on the availability of blood products, Masimo has
created a special program to dramatically reduce the cost of and
increase access to Masimo’s SpHb solutions, as SpHb has been shown to
help clinicians reduce blood transfusions in both low and high blood
loss surgery. This special program will be available wherever the blood
supply is affected by the Zika virus.
@MasimoInnovates |
#Masimo
*Clinical decisions regarding red blood cell transfusions should be
based on the clinician’s judgment considering, among other factors:
patient condition, continuous SpHb monitoring, and laboratory diagnostic
tests using blood samples.
References
-
Imaizumi et al. Continuous and noninvasive hemoglobin monitoring may
reduce excessive intraoperative RBC transfusion. Proceedings from the
16th World Congress of Anaesthesiologists, Hong Kong. Abstract #PR607.
-
Ehrenfeld JM et al. J Blood Disorders Transf. 2014. 5:9. 2.
-
Awada WN et al. J Clin Monit Comput. 2015 Feb 4.
About Masimo
Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive
monitoring technologies. Our mission is to improve patient outcomes and
reduce the cost of care by taking noninvasive monitoring to new sites
and applications. In 1995, the company debuted Masimo SET®
Measure-through Motion and Low Perfusion™ pulse oximetry, which has been
shown in multiple studies to significantly reduce false alarms and
accurately monitor for true alarms. Masimo SET® is estimated
to be used on more than 100 million patients in leading hospitals and
other healthcare settings around the world. In 2005, Masimo introduced
rainbow® Pulse CO-Oximetry technology, allowing noninvasive
and continuous monitoring of blood constituents that previously could
only be measured invasively, including total hemoglobin (SpHb®),
oxygen content (SpOC™), carboxyhemoglobin (SpCO®),
methemoglobin (SpMet®), and more recently, Pleth Variability
Index (PVI®) and Oxygen Reserve Index (ORI™), in addition to
SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo
introduced Root®, an intuitive patient monitoring and
connectivity platform with the Masimo Open Connect™ (MOC-9™) interface.
Masimo is also taking an active leadership role in mHealth with products
such as the Radius-7™ wearable patient monitor and the MightySat™
fingertip pulse oximeter. Additional information about Masimo and its
products may be found at www.masimo.com.
All published clinical studies on Masimo products can be found at http://www.masimo.com/cpub/clinical-evidence.htm.
Forward-Looking Statements
This press release includes forward-looking statements as defined in
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934, in connection with the Private
Securities Litigation Reform Act of 1995. These forward-looking
statements include, among others, statements regarding the potential
effectiveness of SpHb® and the availability of Masimo’s
special program for SpHb solutions. These forward-looking statements are
based on current expectations about future events affecting us and are
subject to risks and uncertainties, all of which are difficult to
predict and many of which are beyond our control and could cause our
actual results to differ materially and adversely from those expressed
in our forward-looking statements as a result of various risk factors,
including, but not limited to: risks related to our assumptions
regarding the repeatability of clinical results; risks related to our
belief that Masimo's unique noninvasive measurement technologies,
including Masimo SpHb, contribute to positive clinical outcomes and
patient safety; risks related to our belief that Masimo noninvasive
medical breakthroughs provide cost-effective solutions with comparable
accuracy and unique advantages, including: immediate and continuous
results that enable earlier treatment without causing invasive trauma in
all patients and in every clinical situation; as well as other factors
discussed in the "Risk Factors" section of our most recent reports filed
with the Securities and Exchange Commission ("SEC"), which may be
obtained for free at the SEC's website at www.sec.gov.
Although we believe that the expectations reflected in our
forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. All forward-looking statements included
in this press release are expressly qualified in their entirety by the
foregoing cautionary statements. You are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of
today's date. We do not undertake any obligation to update, amend or
clarify these statements or the "Risk Factors" contained in our most
recent reports filed with the SEC, whether as a result of new
information, future events or otherwise, except as may be required under
the applicable securities laws.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160909005161/en/
Source: Masimo
Masimo
Evan Lamb, 949-396-3376
elamb@masimo.com